Page 154 - Biomarkers for risk stratification and guidance in heart failure

improvement in survival by natriuretic peptide-guided therapy in patients aged 75 years or less.47,49 Literature-based meta-analysis using aggregate data have suggested that natriuretic peptide-guided treatment may be associated with a 20-30% reduction in all-cause mortality.57-60 Recently a meta-analysis based on individual patient data of 2000 patients included in the major natriuretic peptide- guided therapy studies demonstrated a reduction in all cause mortality of 38% by natriuretic peptide-guided treatment of HF ((HR 0.62 (0.45-0.86); P = 0.004).61 This survival benefit was only seen in patients younger than 75 years (HR 0.62 (0.45- 0.84); P=0.009, see figure 2.
7
General Discussion
Figure 2. Kaplan-Meier survival curves for overall mortality in (A) total group, (B), below age 75 years (n=982) and (C) 75 years or above (n=1018). Figure adapted from an individual patient meta-analysis61
153